Meeting
2016 Gastrointestinal Cancers Symposium
Prognostic influence of clinical biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) receiving sorafenib: A single institution experience.
Authors
Omar Abdel-Rahman
Christie NHS Foundation Trust, Manchester, United Kingdom
Omar Abdel-Rahman , Angela Lamarca , Ismail Salu , Mairead G McNamara , Juan W. Valle , Richard Hubner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 304)
DOI
10.1200/jco.2016.34.4_suppl.304
Abstract #
304
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
First Author: Thomas Yau
Poster
2019 Gastrointestinal Cancers Symposium
Efficacy and tolerability of sorafenib in unresectable/advanced hepatocellular carcinoma patients: Real-life experience in a Hong Kong tertiary liver cancer institute.
First Author: Thomas Cheung Yau
Poster
2018 ASCO Annual Meeting
Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
First Author: Lynn G. Feun
Poster
2018 Gastrointestinal Cancers Symposium
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
First Author: Daniel E. Meyers